OMP-59R5

DRUG3 trials

Sponsors

OncoMed Pharmaceuticals, Inc.

Conditions

Solid TumorsStage IV Pancreatic CancerStage IV Small Cell Lung Cancer

Phase 1

A Dose Escalation Study of OMP-59R5 in Subjects With Solid Tumors

CompletedNCT01277146

OncoMed Pharmaceuticals, Inc.Solid Tumors

Start: 2010-12-31End: 2013-05-31Updated: 2020-09-09

A Phase 1b/2 Study of OMP-59R5 (Tarextumab) in Combination With Nab-Paclitaxel and Gemcitabine in Subjects With Previously Untreated Stage IV Pancreatic Cancer

CompletedNCT01647828

OncoMed Pharmaceuticals, Inc.Stage IV Pancreatic Cancer

Start: 2012-10-31End: 2016-04-30Updated: 2023-02-15

A Phase 1b/2 Study of OMP-59R5 (Tarextumab) in Combination With Etoposide and Platinum Therapy

TerminatedNCT01859741

OncoMed Pharmaceuticals, Inc.Stage IV Small Cell Lung Cancer

Start: 2012-01-07End: 2017-05-08Updated: 2020-09-09

Related Papers

A randomized phase II trial of nab‐paclitaxel and gemcitabine with tarextumab or placebo in patients with untreated metastatic pancreatic cancer

Cancer Medicine2019-07-2680 citations

A phase 1 dose escalation and expansion study of Tarextumab (OMP-59R5) in patients with solid tumors.

2018-12-2859 citations

Abstract 1727: Circulating Tumor Cells (CTCs) in patients with extensive stage small cell lung cancer and their association with clinical outcome

Cancer Research2017-07-01

Results of a randomized phase II trial of an anti-notch 2/3, tarextumab (OMP-59R5, TRXT, anti-Notch2/3), in combination with nab-paclitaxel and gemcitabine (Nab-P+Gem) in patients (pts) with untreated metastatic pancreatic cancer (mPC).

Journal of Clinical Oncology2017-02-0119 citations

The personalized medicine for pancreatic ductal adenocarcinoma patients: The oncologist perspective

Endoscopic Ultrasound2017-01-015 citations

Updated results of phase 1b study of tarextumab (TRXT, anti-Notch2/3) in combination with etoposide and platinum (EP) in patients (pts) with untreated extensive-stage small-cell lung cancer (ED-SCLC).

Journal of Clinical Oncology2016-05-209 citations

Final results of phase Ib of tarextumab (TRXT, OMP-59R5, anti-Notch2/3) in combination with etoposide and platinum (EP) in patients (pts) with untreated extensive-stage small-cell lung cancer (ED-SCLC).

Journal of Clinical Oncology2015-05-2019 citations

Final results of phase Ib of anticancer stem cell antibody tarextumab (OMP-59R5, TRXT, anti-Notch 2/3) in combination with nab-paclitaxel and gemcitabine (Nab-P+Gem) in patients (pts) with untreated metastatic pancreatic cancer (mPC).

Journal of Clinical Oncology2015-01-2014 citations

Phase 1b of anticancer stem cell antibody OMP-59R5 (anti-Notch2/3) in combination with etoposide and cisplatin (EP) in patients (pts) with untreated extensive-stage small-cell lung cancer (ED-SCLC).

Journal of Clinical Oncology2014-05-203 citations

Phase Ib of anticancer stem cell antibody OMP-59R5 (anti-Notch2/3) in combination with nab-paclitaxel and gemcitabine (Nab-P+Gem) in patients (pts) with untreated metastatic pancreatic cancer (mPC).

Journal of Clinical Oncology2014-01-209 citations